Aelix Therapeutics
Dr. Karen Wagner is a General Partner at Ysios Capital where she focuses on therapeutic investments. Dr. Wagner currently serves on the boards of AELIX Therapeutics, Vivet Therapeutics, Xeltis, and Minoryx Therapeutics. Dr. Wagner holds a master’s degree in Molecular Biology and a Ph.D. in Cell Biology, both from the University of Konstanz, Germany.
Dr. Wagner has over 15 years of experience in business development and financing in the biotech/pharma sector working for companies such as F. Hoffmann-La Roche and GlycArt. Previously she was a Consultant in McKinsey & Company’s Global Healthcare Practice.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Aelix Therapeutics
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection.